Cargando…

Decrease in serum anti‐Müllerian hormone level per puncture with laparoscopic ovarian drilling using ultrasonically activated device

PURPOSE: To determine the contributing factor in infertility treatment with laparoscopic ovarian drilling (LOD) to the decrease in serum anti‐Müllerian hormone (AMH) levels in patients with polycystic ovarian syndrome using an ultrasonically activated device. METHODS: A retrospective analysis was pe...

Descripción completa

Detalles Bibliográficos
Autores principales: Ogawa, Shuichi, Atsuki, Yusuke, Shimada, Kazuhiko, Motoyama, Mitsuhiro, Suzuki, Tatsuya, Fujiwara, Hiroyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8499587/
https://www.ncbi.nlm.nih.gov/pubmed/34646074
http://dx.doi.org/10.1002/rmb2.12405
Descripción
Sumario:PURPOSE: To determine the contributing factor in infertility treatment with laparoscopic ovarian drilling (LOD) to the decrease in serum anti‐Müllerian hormone (AMH) levels in patients with polycystic ovarian syndrome using an ultrasonically activated device. METHODS: A retrospective analysis was performed in 60 patients (aged 23–36 years) who received 25–120 punctures in each ovary with LOD treatment from January 2014 to December 2018. RESULTS: The mean decrease in serum AMH level per puncture with LOD was 0.07 ± 0.04 ng/ml in all 60 patients and 0.08 ± 0.04 ng/ml in patients with ≥10 ng/ml preoperative serum AMH level, which was significantly higher than in those with <10 ng/ml (0.05 ± 0.02 ng/ml). The mean decrease in serum AMH level per puncture in patients with body mass index (BMI) < 18.5 kg/m(2) (0.10 ± 0.03 ng/ml) was significantly higher than in those with BMI 18.5–25 kg/m(2) (0.07 ± 0.04 ng/ml) and >25 kg/m(2) (0.06 ± 0.02 ng/ml). CONCLUSIONS: The mean decrease in serum AMH levels per puncture with LOD using an ultrasonically activated device depends on the preoperative serum AMH level and BMI of patients.